- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00709345
Behavioral Intervention to Reduce Novel Antipsychotic Medication Health Risks
Effectiveness of a Cognitive Behavioral Treatment for Reducing Atypical Antipsychotic Medication Health Risks in People With Serious Mental Illness
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Serious mental illness encompasses a large range of symptoms varying in severity, but generally includes symptoms described as both positive and negative. Positive symptoms include confused thinking, delusions, and hallucinations, while negative symptoms include lack of emotion and depression. Because novel or atypical antipsychotic medications target both positive and negative symptoms and have fewer side effects than other medications, they make up the current standard of care for the treatment of many mental illnesses. However, there is growing concern that the psychiatric benefits associated with atypical antipsychotic medications are offset by serious negative medical consequences, including weight gain, obesity-related cardiovascular risk, insulin resistance, and diabetes. Behavioral interventions that aim to help people coping with serious mental illness to reduce weight, sustain weight loss, and achieve better fitness may improve the risk/benefit ratio of atypical antipsychotic medications. A small-group cognitive behavioral intervention that provides peer and structural risk-reduction support may be the most beneficial means of promoting healthy eating and exercise habits in people with serious mental illness who are living in group homes. This study will evaluate the effectiveness of a small-group cognitive behavioral intervention conducted in group homes for reducing significant medical risk factors often associated with people who have a serious mental illness and are taking atypical antipsychotic medications.
Participation in this study will last about 18 months through follow-up. All participants will undergo baseline assessments that will include the following: measurements of diet and exercise patterns, using self-report and observational methods; measurements of weight, body mass index, body fat distribution, pulse rate, and blood pressure; blood draws; and questions about psychological well-being and quality of life. Group homes will then be assigned randomly to provide participating residents with either the cognitive behavioral intervention or the time-matched attention control program. Participants in both groups will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. The cognitive behavioral sessions will focus on promoting healthy behaviors, dieting, and exercise. The time-matched attention control sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts. After completing treatment, all participants will receive 6 monthly 1-hour booster sessions of their assigned treatments. They will also repeat the baseline assessments 3 times over the following 12 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Resides in one of the designated group homes
Exclusion Criteria:
- Sufficiently impaired because of a psychiatric illness, as reflected in mental status in which informed judgment about study participation cannot be assured at the time of study entry
- Medical contraindication to study participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group Home
Participants will receive cognitive behavioral sessions.
|
Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator.
After completing treatment, participants will also receive 6 monthly 1-hour booster sessions.
All sessions will focus on promoting healthy behaviors, dieting, and exercise.
|
Active Comparator: Control
Participants will receive time-matched attention control sessions.
|
Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator.
After completing treatment, participants will also receive 6 monthly 1-hour booster sessions.
All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Average weight loss; body mass index; and effects across other behavioral, clinical, physiological, and ancillary measures
Time Frame: Measured at Month 12
|
Measured at Month 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Ability of behavioral intervention to offset significant medical risk factors often associated with people living with mental illness
Time Frame: Measured at Month 12
|
Measured at Month 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: David W. Seal, PhD, Medical College of Wisconsin
- Study Director: Carol L. Galletly, JD, PhD, Medical College of Wisconsin
- Study Director: Timothy L. McAuliffe, PhD, Medical College of Wisconsin
- Study Director: Anton M. Somlai, EdD, Medical College of Wisconsin
- Study Director: Jill T. Owczarzak, PhD, Medical College of Wisconsin
- Study Director: Thomas W. Heinrich, MD, Medical College of Wisconsin
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01MH078576 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Illness
-
VA Office of Research and DevelopmentNot yet recruiting
-
Shalvata Mental Health CenterRecruitingSevere Mental IllnessIsrael
-
Indiana UniversityCompleted
-
Yale UniversityNational Institute of Mental Health (NIMH)CompletedSerious Mental IllnessUnited States
-
Temple UniversityNot yet recruitingSerious Mental Illness
-
Shalvata Mental Health CenterRecruitingSevere Mental IllnessIsrael
-
VA Office of Research and DevelopmentRecruitingSerious Mental IllnessUnited States
-
King's College LondonSouth London and Maudsley NHS Foundation TrustCompletedSevere Mental IllnessUnited Kingdom
-
VA Office of Research and DevelopmentCompleted
-
VA Office of Research and DevelopmentUS Department of Veterans AffairsCompletedMental Illness | Physical IllnessUnited States
Clinical Trials on Cognitive behavioral sessions
-
Egyptian Medical SyndicateNot yet recruitingSubstance Use Disorders
-
Northwestern UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Diseases | Peripheral Vascular DiseasesUnited States
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)CompletedHIV Infections | Substance Use | Mental Health | Family Relations | Risky Sexual Behavior | Physical Health
-
University of California, Los AngelesCompletedQuality of Life | Mental Health | Family Relations | Physical HealthUnited States
-
University of California, Los AngelesCenters for Disease Control and Prevention, ChinaCompletedPatient Satisfaction | HIV-related Stigma | Provider-patient InteractionUnited States
-
CAMC Health SystemCompletedVocal Cord DysfunctionUnited States
-
University of MichiganNot yet recruitingDepression | Type 2 Diabetes
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)CompletedMajor Depressive DisorderUnited States
-
Brain & Body Health FoundationUnknownTraumatic Brain Injury | Concussion | Mild Cognitive DisorderUnited States
-
Barcelonabeta Brain Research Center, Pasqual Maragall...CompletedPsychological Support to Caregivers of Azlheimer's PatientsSpain